Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech

Dow Jones

07/07

Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech.

The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year.

The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China.

Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories.

Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea.

Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 06, 2026 17:53 ET (21:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2649674118"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649674118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649674118?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 05:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649674118","market":"other","top_or_hot":-1,"title":"Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> surged after the company received a $25 million upfront payment as part of a licensing deal with <a href=\"https://laohu8.com/S/688278\">Xiamen Amoytop Biotech</a>. \n</p>\n<p>\n  The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year. \n</p>\n<p>\n  The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China. \n</p>\n<p>\n  Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories. \n</p>\n<p>\n  Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea. \n</p>\n<p>\n  Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 17:53 ET (21:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-07 05:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> surged after the company received a $25 million upfront payment as part of a licensing deal with <a href=\"https://laohu8.com/S/688278\">Xiamen Amoytop Biotech</a>. \n</p>\n<p>\n  The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year. \n</p>\n<p>\n  The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China. \n</p>\n<p>\n  Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories. \n</p>\n<p>\n  Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea. \n</p>\n<p>\n  Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 17:53 ET (21:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688278","symbol_name":"特宝生物","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649674118","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649674118","pubTimestamp":1783374780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech.The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year.The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China.Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories.Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea.Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter.Write to Grace Yoon at grace.yoon@","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688278":"特宝生物","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","BK0239":"医药制造","BK4588":"碎股","XBI":"SPDR S&P Biotech ETF","BK4505":"高瓴资本持仓","BK4139":"生物科技","ALGS":"Aligos Therapeutics, Inc."},"translate_title":"厦门淘拓生物科技支付2500万美元后，Aligos Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688278":0.9,"ALGS":1.5,"XBI":1.5},"content_text":"Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech. \n\n\n  The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year. \n\n\n  The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China. \n\n\n  Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories. \n\n\n  Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea. \n\n\n  Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 06, 2026 17:53 ET (21:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}